Asymmetric Synthesis of Macrolide Antibiotics
Asymmetric Synthesis of Macrolide Antibiotics
批准号:
9277048
负责人:
JAMES L LEIGHTON
金额:
$8.0万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-08-01 至 2018-04-30
关键词:
3-hydroxybutanalAlkynesAntibodiesAntibody-drug conjugatesBindingBiologicalCancer cell lineClinicClinicalComplexCytotoxic agentDevelopmentEvaluationGoalsHealthHumanMacrolide AntibioticsMacrolidesMalignant NeoplasmsMarinesMethodsMicrotubulesMitoticNatural ProductsOxidation-ReductionPharmaceutical PreparationsPreparationReactionSeriesSiteSourceStagingSynthesis ChemistryTimeTubulinanalogchemical synthesischemotherapeutic agentclinical efficacydesigndiketonefrontiermarine natural productmethod developmentnanomolaroperationoxidationpre-clinicalpreclinical evaluationresearch clinical testingspongistatin 1success
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Non-aromatic polyketide natural products of marine origin are often characterized by both significant structural complexity and extraordinary biological activities. Because these exciting compounds are not typically available in any meaningful quantities from natural sources, total chemical synthesis is the only means by which sufficient amounts of material may be accessed for the full biological/preclinical evaluation of these compounds. No natural product better exemplifies this class of compound than spongistatin 1. This extraordinarily complex and precious marine natural product has an average IC50 value against the NCI panel of 60 human cancer cell lines of 0.12 pM. The ultimate goal of this proposal is to adapt spongistatin 1 for use in an antibody-drug conjugate (ADC) construct, by way of the design, synthesis and evaluation of a series of analogs of spongistatin 1 to identify appropriate linker sites for bioconjugation and to identify a significanly structurally simplified analog that retains the sub-nanomolar potency of the natural product. Our focus on an ADC approach derives mainly from two considerations: 1) this approach requires far less drug material than conventional approaches, rendering the synthesis of the kinds of amounts required for full clinical evaluation a significantly more realistic proposition, and 2) th low pM potency of spongistatin 1 renders it an ideal candidate for use in an ADC, as so little drug material makes it to the target that extraordinary potency is required for any meaningful clinical efficacy. In order to achieve these goals, we will continue to develop synthetic methods for the synthesis of polyketide natural products that are characterized by unprecedented levels of step-economy, efficiency, and scalability to continue to push the frontiers of efficiency in the
chemical synthesis. We will then apply these methods to the development of a synthesis of spongistatin 1 that may easily be adapted for use in the preparation of the designed analogs. Finally, we will identify and synthesize significant quantities of the most significantly structuraly simplified compound equipped with a linker that retains the low pM potency of spongistatin 1.
期刊论文(35)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1021/ja201467z
发表时间:
2011-05-18
期刊:
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
影响因子:
15
作者:
[Harrison, Tyler J., Ho, Stephen, Leighton, James L.]
通讯作者:
Leighton, James L.
DOI:
10.1021/ol500051e
发表时间:
2014-02-21
期刊:
ORGANIC LETTERS
影响因子:
5.2
作者:
[Foley, Corinne N., Leighton, James L.]
通讯作者:
Leighton, James L.
DOI:
10.1021/ja0283201
发表时间:
2003-01
期刊:
Journal of the American Chemical Society
影响因子:
15
作者:
[Darby R Schmidt;Steven J. O'Malley;J. L. Leighton]
通讯作者:
Darby R Schmidt;Steven J. O'Malley;J. L. Leighton
Tandem Intramolecular Alkyne Silylformylation-Allylsilylation: A Case of Remote 1,5-Asymmetric Induction Financial support was provided by the National Institutes of Health (National Institute of General Medical Sciences, GM58133). We are grateful to Bris
串联分子内炔基甲酰化-烯丙基甲硅烷基化:远程 1,5-不对称诱导案例 财务支持由美国国立卫生研究院(国立普通医学科学研究所,GM58133)提供。
DOI:
--
发表时间:
2001
期刊:
Angewandte Chemie (International ed. in English)
影响因子:
--
作者:
[O'Malley,StevenJ., Leighton,JamesL.]
通讯作者:
Leighton,JamesL.
Divergent synthesis of complex polyketide-like macrolides from a simple polyol fragment.
从简单的多元醇片段发散合成复杂的聚酮化合物类大环内酯。
DOI:
10.1021/ol052373g
发表时间:
2005
期刊:
Organic letters
影响因子:
5.2
作者:
[Zacuto,MichaelJ, Leighton,JamesL]
通讯作者:
Leighton,JamesL
共 21 条
Asymmetric Synthesis of Macrolide Antibiotics
-
批准号:7863511
-
项目类别:
-
资助金额:$13.5万
-
财政年份:2009
-
负责人:JAMES L LEIGHTON
-
依托单位:
TOTAL SYNTHESIS OF RAS FARNESYL TRANSFERASE INHIBITOR
-
批准号:2883092
-
项目类别:
-
资助金额:$16.56万
-
财政年份:1999
-
负责人:JAMES L LEIGHTON
-
依托单位:
TOTAL SYNTHESIS OF THE FARNESY TRANSFERASE INHIBITOR
-
批准号:6386525
-
项目类别:
-
资助金额:$17.55万
-
财政年份:1999
-
负责人:JAMES L LEIGHTON
-
依托单位:
TOTAL SYNTHESIS OF THE FARNESY TRANSFERASE INHIBITOR
-
批准号:6182020
-
项目类别:
-
资助金额:$17.05万
-
财政年份:1999
-
负责人:JAMES L LEIGHTON
-
依托单位:
TOTAL SYNTHESIS OF THE FARNESY TRANSFERASE INHIBITOR
-
批准号:6526049
-
项目类别:
-
资助金额:$18.07万
-
财政年份:1999
-
负责人:JAMES L LEIGHTON
-
依托单位:
Asymmetric Synthesis of Macrolide Antibiotics
-
批准号:6785496
-
项目类别:
-
资助金额:$32.13万
-
财政年份:1998
-
负责人:JAMES L LEIGHTON
-
依托单位:
Asymmetric Synthesis of Macrolide Antibiotics
-
批准号:8246454
-
项目类别:
-
资助金额:$37.36万
-
财政年份:1998
-
负责人:JAMES L LEIGHTON
-
依托单位:
Asymmetric Synthesis of Macrolide Antibiotics
-
批准号:7654416
-
项目类别:
-
资助金额:$33.67万
-
财政年份:1998
-
负责人:JAMES L LEIGHTON
-
依托单位:
ASYMMETRIC SYNTHESIS OF MACROLIDE ANTIBIOTICS
-
批准号:6019488
-
项目类别:
-
资助金额:$18.92万
-
财政年份:1998
-
负责人:JAMES L LEIGHTON
-
依托单位:
Asymmetric Synthesis of Macrolide Antibiotics
-
批准号:8055001
-
项目类别:
-
资助金额:$33.47万
-
财政年份:1998
-
负责人:JAMES L LEIGHTON
-
依托单位:
Asymmetric Synthesis of Macrolide Antibiotics
-
批准号:6775182
-
项目类别:
-
资助金额:$1.3万
-
财政年份:1998
-
负责人:JAMES L LEIGHTON
-
依托单位:
Asymmetric Synthesis of Macrolide Antibiotics
-
批准号:8325822
-
项目类别:
-
资助金额:$4.26万
-
财政年份:1998
-
负责人:JAMES L LEIGHTON
-
依托单位:
Asymmetric Synthesis of Marcolide Antibiotics
-
批准号:9267472
-
项目类别:
-
资助金额:$34.74万
-
财政年份:1998
-
负责人:JAMES L LEIGHTON
-
依托单位:
Asymmetric Synthesis of Macrolide Antibiotics
-
批准号:7788113
-
项目类别:
-
资助金额:$33.61万
-
财政年份:1998
-
负责人:JAMES L LEIGHTON
-
依托单位:
Asymmetric Synthesis of Macrolide Antibiotics
-
批准号:6923601
-
项目类别:
-
资助金额:$30.65万
-
财政年份:1998
-
负责人:JAMES L LEIGHTON
-
依托单位:
ASYMMETRIC SYNTHESIS OF MACROLIDE ANTIBIOTICS
-
批准号:2685152
-
项目类别:
-
资助金额:$18.99万
-
财政年份:1998
-
负责人:JAMES L LEIGHTON
-
依托单位:
ASYMMETRIC SYNTHESIS OF MACROLIDE ANTIBIOTICS
-
批准号:6386992
-
项目类别:
-
资助金额:$19.42万
-
财政年份:1998
-
负责人:JAMES L LEIGHTON
-
依托单位:
ASYMMETRIC SYNTHESIS OF MACROLIDE ANTIBIOTICS
-
批准号:6181251
-
项目类别:
-
资助金额:$19.17万
-
财政年份:1998
-
负责人:JAMES L LEIGHTON
-
依托单位:
Asymmetric Synthesis of Marcolide Antibiotics
-
批准号:8632159
-
项目类别:
-
资助金额:$22.68万
-
财政年份:1998
-
负责人:JAMES L LEIGHTON
-
依托单位:
Asymmetric Synthesis of Macrolide Antibiotics
-
批准号:6542310
-
项目类别:
-
资助金额:$33.49万
-
财政年份:1998
-
负责人:JAMES L LEIGHTON
-
依托单位:
海外基金